Difference between revisions of "Diazoxide"
m (1 revision) |
|
(No difference)
| |
Latest revision as of 10:23, 20 September 2010
| File:Diazoxide.svg | |
| Systematic (IUPAC) name | |
|---|---|
|
7-chloro-3-methyl-4H-1,2,4-benzothiadiazine 1,1-dioxide | |
| Clinical data | |
| Pregnancy category | |
| Routes of administration | Oral, intravenous |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Protein binding | 90% |
| Metabolism | Hepatic oxidation and sulfate conjugation |
| Biological half-life | 21-45 hours |
| Excretion | Renal |
| Identifiers | |
| CAS Number | 364-98-7 |
| ATC code | C02DA01 (WHO) V03AH01 |
| PubChem | CID 3019 |
| IUPHAR/BPS | 2409 |
| DrugBank | APRD00914 |
| ChemSpider | 2911 |
| Chemical data | |
| Formula | C8H7ClN2O2S |
| Molar mass | 230.672 g/mol[[Script error: No such module "String".]] |
| Script error: No such module "collapsible list". | |
| (verify) | |
Diazoxide is a potassium channel activator, which causes local relaxation in smooth muscle by increasing membrane permeability to potassium ions. This switches off voltage-gated calcium ion channels which inhibits the generation of an action potential.
Uses
It is used as a vasodilator in the treatment of acute hypertension or malignant hypertension.[1]
It is also used to decrease hypoglycemia due to the secretion of insulin in disease states such as insulinoma (a tumor producing insulin)[2] or congenital hyperinsulinism.
Chemistry
Rubin, A. A.; Roth, F. E.; Winbury, M. M.; Topliss, J. G.; Sherlock, M. H.; Sperber, N.; Black, J. (1961). "New Class of Antihypertensive Agents". Science. 133: 2067. doi:10.1126/science.133.3470.2067.
References
Cite error: Invalid <references> tag;
parameter "group" is allowed only.
<references />, or <references group="..." />de:Diazoxid fr:Diazoxide hr:Diazoksid it:Diazossido
pl:Diazoksyd
